Generation of Genetically Modified Rats Using CRISPR/Cas9 Genome-Editing System to Reveal Novel Vitamin D Actions

Article Sidebar

10-Sept-2558.pdf
Published Sep 26, 2021
DOI: https://doi.org/10.18103/mra.v9i9.2558

Downloads

Download data is not yet available.

Main Article Content

Miyu Nishikawa
Department of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama, 939-0398, Japan
Kaori Yasuda
Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
Hiroki Mano
Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
Shinichi Ikushiro
Department of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama, 939-0398, Japan
Toshiyuki Sakaki
Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan

Abstract

We previously revealed that the anti-proliferative activity of 25-hydroxyvitamin D3 (25(OH)D3) in human prostate PZ-HPV-7 cells depends on the direct action of 25(OH)D3 through the vitamin D receptor (VDR). We then attempted to confirm the direct action of 25(OH)D3 in vivo using Cyp27b1 knockout (KO) mice. Daily administration of 25(OH)D3 at 250 μg/kg bw/day rescued the rachitic conditions in Cyp27b1 KO mice. The plasma levels of calcium, phosphorus, and parathyroid hormonea as well as the bone mineral density and female sexual cycle were normalized via the administration of 25(OH)D3. These results strongly suggest the direct action of 25(OH)D3. However, to our surprise, normal levels of 1a,25(OH)2D3 were detected in the plasma of Cyp27b1 KO mice, probably due to Cyp27a1, which has a weak 1a-hydroxylation activity toward 25(OH)D3.


Next, we generated a novel in vivo system using genetically modified (GM) rats deficient in the Cyp27b1 or Vdr gene to reveal the molecular mechanisms of vitamin D action. Human type II rickets model rats with mutant Vdr (R270L), which recognizes 1,25(OH)2D3 with an affinity equivalent to that of 25(OH)D3, were also generated. Cyp27b1-knockout (KO), Vdr-KO, and Vdr (R270L) rats showed symptoms of rickets, including growth retardation and abnormal bone formation. Among these model animals, Cyp27b1-KO rats had notably low levels of calcium in the blood and the most severe growth retardation, while Vdr-KO rats showed abnormal skin formation and alopecia. Administration of 25(OH)D3 restored rickets symptoms in Cyp27b1-KO and Vdr (R270L) rats. As shown in Cyp27b1-KO mice, 1,25(OH)2D3 was also synthesized in Cyp27b1-KO rats. In contrast, the effects of 25(OH)D3 on Vdr (R270L) rats strongly suggest that 25(OH)D3 exerts a direct action via VDR-genomic pathways. These results suggest that our novel in vivo system containing three different types of GM rats is useful for elucidating the molecular mechanism of vitamin D action.

Keywords: vitamin D, vitamin D receptor, genome editing, CYP27B1, rickets

Article Details

How to Cite
NISHIKAWA, Miyu et al. Generation of Genetically Modified Rats Using CRISPR/Cas9 Genome-Editing System to Reveal Novel Vitamin D Actions. Medical Research Archives, [S.l.], v. 9, n. 9, sep. 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2558>. Date accessed: 19 apr. 2024. doi: https://doi.org/10.18103/mra.v9i9.2558.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 9 No 9 (2021): Vol.9 Issue 9 September 2021
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010;9(12):941-955.
2. Sakaki T, Kagawa N, Yamamoto K, et al. Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005;10:119-134.
3. Haussler MR, Whitfield GK, Kaneko I, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013;92(2):77-98.
4. Norman AW, Bishop JE, Collins ED, et al. Differing shapes of 1 alpha,25-dihydroxyvitamin D3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: a status report. J Steroid Biochem Mol Biol. 1996;56 (1-6 Spec No): 13-22.
5. Mizwicki MT, Norman AW. The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. Sci Signal. 2009;2(75): re4; 10.1126/scisignal.275re4.
6. Hii CS, Ferrante A. The Non-Genomic Actions of Vitamin D. Nutrients. 2016;8(3): 135; 10.3390/nu8030135.
7. Munetsuna E, Kawanami R, Nishikawa M, et al. Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells. Mol Cell Endocrinol. 2014;382(2): 960-970.
8. Masuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther. 2006;5(4),:797-808.
9. Asano L, Watanabe M, Ryoden Y, et al. Vitamin D Metabolite, 25-Hydroxyvitamin D, Regulates Lipid Metabolism by Inducing Degradation of SREBP/SCAP. Cell Chem Biol. 2017;24(2):207-217.
10. Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cel Endocrinol. 2011;347(1-2):90-96.
11. Skorija K, Cox M, Sisk JM, et al. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrinol. 2005;19(4):855-862.
12. Lou YR, Laaksi I, Syvälä H, et al. 25-hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB J. 2004;18(2):332-334.
13. Peng X, Hawthorne M, Vaishnav A, et al. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat. 2009;113(1):31-41.
14. Lou YR, Molnár F, Peräkylä M, et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol. 2010;118(3):162-170.
15. Verone-Boyle AR, Shoemaker S, Attwood K, et al. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo. Oncotarget. 2016;7(1):995-1013.
16. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev. 1995;16(2):200-257.
17. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289(1):F8-28.
18. Nishikawa M, Yasuda K, Takamatsu M, et al. Generation of 1,25-dihydroxyvitamin D3 in Cyp27b1 knockout mice by treatment with 25-hydroxyvitamin D3 rescued their rachitic phenotypes. J Steroid Biochem Mol Biol. 2019;185:71-79.
19. Sawada N, Sakaki T, Ohta M, et al. Metabolism of vitamin D(3) by human CYP27A1. Biochem Biophys Res Commun. 2000;273(3):977-984.
20. Kristjansson K, Rut AR, Hewison M, et al. Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. J Clin Invest. 1993;92(1):12-16.
21. Malloy PJ, Feldman D. Genetic disorders and defects in vitamin D action. Endocr Metab Clin. 2010;39(2):333– 346.
22. Nakabayashi M, Tsukahara Y, Iwasaki-Miyamoto Y, et al. Crystal structures of hereditary vitamin D-resistant rickets-associated vitamin D receptor mutants R270L and W282R bound to 1,25-dihydroxyvitamin D3 and synthetic ligands. J Med Chem. 2013;56(17):6745-6760.
23. Nishikawa M, Yasuda K, Takamatsu M, et al. Generation of novel genetically modified rats to reveal the molecular mechanisms of vitamin D actions. Sci Rep. 2020;10(1):5677.